Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancer
Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not cl...
Saved in:
| Published in | Cancer science Vol. 112; no. 1; pp. 296 - 304 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley & Sons, Inc
01.01.2021
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1347-9032 1349-7006 1349-7006 |
| DOI | 10.1111/cas.14674 |
Cover
| Abstract | Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular‐based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10‐329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular‐based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first‐line chemotherapy.
Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies; however, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic assay. We found that CGP testing could be feasible in Japanese clinical practice for chemotherapy‐naïve patients with these cancers, and that CGP testing might be a useful tool to identify a potentially effective first‐line treatment, which will lead to the establishment of precision cancer medicine. |
|---|---|
| AbstractList | Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular‐based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10‐329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular‐based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first‐line chemotherapy. Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular‐based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10‐329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular‐based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first‐line chemotherapy. Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies; however, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic assay. We found that CGP testing could be feasible in Japanese clinical practice for chemotherapy‐naïve patients with these cancers, and that CGP testing might be a useful tool to identify a potentially effective first‐line treatment, which will lead to the establishment of precision cancer medicine. Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne ® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular‐based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10‐329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular‐based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first‐line chemotherapy. Comprehensive genomic profiling (CGP) testing by next-generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first-line chemotherapy could be clinically useful is not clear. We conducted this single-center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy-naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular-based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10-329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular-based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first-line chemotherapy.Comprehensive genomic profiling (CGP) testing by next-generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first-line chemotherapy could be clinically useful is not clear. We conducted this single-center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy-naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular-based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10-329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular-based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first-line chemotherapy. Comprehensive genomic profiling (CGP) testing by next-generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first-line chemotherapy could be clinically useful is not clear. We conducted this single-center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy-naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular-based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10-329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular-based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first-line chemotherapy. Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne ® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular‐based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10‐329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular‐based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first‐line chemotherapy. Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies; however, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne ® companion diagnostic assay. We found that CGP testing could be feasible in Japanese clinical practice for chemotherapy‐naïve patients with these cancers, and that CGP testing might be a useful tool to identify a potentially effective first‐line treatment, which will lead to the establishment of precision cancer medicine. |
| Author | Funakoshi, Taro Muto, Manabu Quy, Pham Nguyen Yamada, Takahiro Nomura, Motoo Doi, Keitaro Tamaoki, Masashi Nishigaki, Masakazu Matsumoto, Shigemi Yamamoto, Yoshihiro Kanai, Masashi Yokoyama, Akira Hirohashi, Kenshiro Kou, Tadayuki Kondo, Tomohiro Yoshioka, Masahiro Fukuyama, Keita Yamada, Atsushi Minamiguchi, Sachiko Matsubara, Junichi Sakamori, Yuichi |
| AuthorAffiliation | 6 Present address: Genetic Counseling International University of Health and Welfare Graduate School Tokyo Japan 5 Present address: Department of Gastroenterology and Hepatology Tazuke Kofukai Medical Research Institute Kitano Hospital Osaka Japan 1 Department of Clinical Oncology Kyoto University Hospital Kyoto Japan 4 Clinical Genetics Unit Kyoto University Hospital Kyoto Japan 2 Research Fellow of Japan Society for the Promotion of Science Tokyo Japan 3 Department of Diagnostic Pathology Kyoto University Hospital Kyoto Japan |
| AuthorAffiliation_xml | – name: 3 Department of Diagnostic Pathology Kyoto University Hospital Kyoto Japan – name: 5 Present address: Department of Gastroenterology and Hepatology Tazuke Kofukai Medical Research Institute Kitano Hospital Osaka Japan – name: 2 Research Fellow of Japan Society for the Promotion of Science Tokyo Japan – name: 1 Department of Clinical Oncology Kyoto University Hospital Kyoto Japan – name: 4 Clinical Genetics Unit Kyoto University Hospital Kyoto Japan – name: 6 Present address: Genetic Counseling International University of Health and Welfare Graduate School Tokyo Japan |
| Author_xml | – sequence: 1 givenname: Tomohiro orcidid: 0000-0001-5102-2654 surname: Kondo fullname: Kondo, Tomohiro organization: Research Fellow of Japan Society for the Promotion of Science – sequence: 2 givenname: Junichi surname: Matsubara fullname: Matsubara, Junichi organization: Kyoto University Hospital – sequence: 3 givenname: Pham Nguyen surname: Quy fullname: Quy, Pham Nguyen organization: Kyoto University Hospital – sequence: 4 givenname: Keita surname: Fukuyama fullname: Fukuyama, Keita organization: Kyoto University Hospital – sequence: 5 givenname: Motoo surname: Nomura fullname: Nomura, Motoo organization: Kyoto University Hospital – sequence: 6 givenname: Taro surname: Funakoshi fullname: Funakoshi, Taro organization: Kyoto University Hospital – sequence: 7 givenname: Keitaro surname: Doi fullname: Doi, Keitaro organization: Kyoto University Hospital – sequence: 8 givenname: Yuichi surname: Sakamori fullname: Sakamori, Yuichi organization: Kyoto University Hospital – sequence: 9 givenname: Masahiro surname: Yoshioka fullname: Yoshioka, Masahiro organization: Kyoto University Hospital – sequence: 10 givenname: Akira surname: Yokoyama fullname: Yokoyama, Akira organization: Kyoto University Hospital – sequence: 11 givenname: Masashi surname: Tamaoki fullname: Tamaoki, Masashi organization: Kyoto University Hospital – sequence: 12 givenname: Tadayuki orcidid: 0000-0001-6397-2446 surname: Kou fullname: Kou, Tadayuki organization: Kyoto University Hospital – sequence: 13 givenname: Kenshiro surname: Hirohashi fullname: Hirohashi, Kenshiro organization: Kyoto University Hospital – sequence: 14 givenname: Atsushi surname: Yamada fullname: Yamada, Atsushi organization: Kyoto University Hospital – sequence: 15 givenname: Yoshihiro orcidid: 0000-0003-0194-9579 surname: Yamamoto fullname: Yamamoto, Yoshihiro organization: Kyoto University Hospital – sequence: 16 givenname: Sachiko surname: Minamiguchi fullname: Minamiguchi, Sachiko organization: Kyoto University Hospital – sequence: 17 givenname: Masakazu surname: Nishigaki fullname: Nishigaki, Masakazu organization: Kyoto University Hospital – sequence: 18 givenname: Takahiro surname: Yamada fullname: Yamada, Takahiro organization: Kyoto University Hospital – sequence: 19 givenname: Masashi orcidid: 0000-0002-6954-4474 surname: Kanai fullname: Kanai, Masashi organization: Kyoto University Hospital – sequence: 20 givenname: Shigemi surname: Matsumoto fullname: Matsumoto, Shigemi organization: Kyoto University Hospital – sequence: 21 givenname: Manabu orcidid: 0000-0002-3127-8203 surname: Muto fullname: Muto, Manabu email: mmuto@kuhp.kyoto-u.ac.jp organization: Kyoto University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33007138$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1uFDEQhS0URH5gwQVQS2zCohO77ba7N0jRiD8pEgtALK0ad3naUbfd2D0TzY4jcBMOwU04CZ5MiCASeFOW6qunV_WOyYEPHgl5yugZy-_cQDpjQirxgBwxLtpSUSoPbv6qbCmvDslxSleUcila8Ygcck6pYrw5Ip8XYZwi9uiT22CxQh9GZ4opBusG51eFDbGYYHbo51Rcu7kvTI9jmHuMMG1_fv3m4cf3PAndBrzBrjC7Eh-ThxaGhE9u6wn59PrVx8Xb8vL9m3eLi8vS1DUXZXZPeS2lsXxJlZJLYTizLVjbIVhlkNFKNsoooEiBWdU1AgzUikpOqxb4CXm5153WyxE7k21GGPQU3QhxqwM4_XfHu16vwkYr1eR7VFng9FYghi9rTLMeXTI4DOAxrJOuhGgErRVTGX1-D70K6-jzeplSQsk2XzVTz_50dGfl980z8GIPmBhSimjvEEb1Lk-d89Q3eWb2_B5r3JzTCLtl3PC_iWs34Pbf0npx8WE_8QvkXbPo |
| CitedBy_id | crossref_primary_10_3390_curroncol29100573 crossref_primary_10_1007_s10147_024_02533_z crossref_primary_10_1055_s_0043_1761624 crossref_primary_10_2958_suizo_39_316 crossref_primary_10_1002_gcc_23143 crossref_primary_10_3390_jpm12030413 crossref_primary_10_1002_cam4_5349 crossref_primary_10_1200_GO_22_00135 crossref_primary_10_1007_s12032_023_02011_y crossref_primary_10_1038_s41598_021_99364_z crossref_primary_10_3390_cancers16081504 crossref_primary_10_1080_13696998_2022_2080463 crossref_primary_10_1111_cas_16165 crossref_primary_10_1111_cas_15951 crossref_primary_10_1111_cas_16446 crossref_primary_10_1111_cas_15586 crossref_primary_10_1002_jgh3_12965 crossref_primary_10_1007_s10147_024_02628_7 crossref_primary_10_3390_cancers13194803 crossref_primary_10_1016_j_neo_2022_100834 crossref_primary_10_2340_1651_226X_2024_39918 crossref_primary_10_1007_s10147_022_02176_y crossref_primary_10_1111_jgh_16304 crossref_primary_10_1007_s00535_023_02037_z |
| Cites_doi | 10.1200/JOP.2014.002303 10.1038/s41591-019-0407-5 10.1016/S1470-2045(20)30074-7 10.1056/NEJMra1615014 10.1038/nm.4333 10.1111/cas.13265 10.1093/annonc/mdz080 10.1111/cas.14290 10.1093/annonc/mdw235 10.1038/gim.2016.190 10.1111/cas.13730 10.1200/JCO.2016.71.9807 10.1111/cas.13969 10.1093/jjco/hyw018 10.1016/S1470-2045(15)00188-6 10.1056/NEJMoa0805019 10.1200/JCO.2019.37.15_suppl.3003 10.1016/S1470-2045(20)30157-1 10.1200/PO.16.00046 10.1038/nbt.2696 10.1111/cas.13968 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1111/cas.14674 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | KONDO et al |
| EISSN | 1349-7006 |
| EndPage | 304 |
| ExternalDocumentID | PMC7780032 33007138 10_1111_cas_14674 CAS14674 |
| Genre | article Journal Article Observational Study |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Chugai Pharmaceutical Co., Ltd. – fundername: ; |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACCMX ACSCC ACXQS ADBBV ADKYN ADPDF ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT 7X7 88E 8FI 8FJ AAFWJ AAYXX ABUWG CITATION FYUFA HMCUK M1P PHGZM PHGZT PSQYO UKHRP CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AAMMB AEFGJ AGXDD AIDQK AIDYY AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c5534-11103566cf3b0776b4c31f9affdeaf7ce102687c7a0e0a1f7d84aca57063029a3 |
| IEDL.DBID | 24P |
| ISSN | 1347-9032 1349-7006 |
| IngestDate | Thu Aug 21 17:44:01 EDT 2025 Fri Sep 05 06:32:09 EDT 2025 Wed Aug 13 07:05:51 EDT 2025 Thu Apr 03 07:08:54 EDT 2025 Tue Jul 01 01:31:09 EDT 2025 Thu Apr 24 22:59:01 EDT 2025 Wed Jan 22 16:30:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | precision cancer medicine comprehensive genomic profiling druggable genomic alteration actionable genomic alteration gastrointestinal cancer |
| Language | English |
| License | Attribution-NonCommercial 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5534-11103566cf3b0776b4c31f9affdeaf7ce102687c7a0e0a1f7d84aca57063029a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Clinical trial information: UMIN000034830. |
| ORCID | 0000-0001-6397-2446 0000-0003-0194-9579 0000-0002-3127-8203 0000-0002-6954-4474 0000-0001-5102-2654 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14674 |
| PMID | 33007138 |
| PQID | 2474769007 |
| PQPubID | 4378882 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7780032 proquest_miscellaneous_2448405717 proquest_journals_2474769007 pubmed_primary_33007138 crossref_primary_10_1111_cas_14674 crossref_citationtrail_10_1111_cas_14674 wiley_primary_10_1111_cas_14674_CAS14674 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2021 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Tokyo – name: Hoboken |
| PublicationTitle | Cancer science |
| PublicationTitleAlternate | Cancer Sci |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2017; 108 2017; 1 2015; 16 2019; 30 2020 2018; 379 2013; 31 2015; 11 2017; 35 2019; 37 2017; 23 2019; 25 2020; 38 2020; 111 2017; 19 2009; 360 2018; 109 1046O; 29 2020; 21 2016; 27 2016; 46 2019; 110 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_12_1 Chakravarty D (e_1_2_9_13_1) 2017; 1 Nakamura Y (e_1_2_9_22_1) 2020; 38 e_1_2_9_14_1 e_1_2_9_17_1 Dalton WB (e_1_2_9_15_1) 2017; 1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Ho AL (e_1_2_9_25_1); 29 e_1_2_9_9_1 e_1_2_9_26_1 |
| References_xml | – volume: 29 year: 1046O article-title: Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations publication-title: Ann Oncol – volume: 111 start-page: 687 year: 2020 end-page: 699 article-title: Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients publication-title: Cancer Sci – volume: 46 start-page: 399 year: 2016 end-page: 406 article-title: The possibility of clinical sequencing in the management of cancer publication-title: Jpn J Clin Oncol – volume: 11 start-page: 135 year: 2015 end-page: 136 article-title: Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline publication-title: J Oncol Pract – volume: 379 start-page: 1452 year: 2018 end-page: 1462 article-title: Classification, ontology, and precision medicine publication-title: N Engl J Med – volume: 25 start-page: 744 year: 2019 end-page: 750 article-title: Molecular profiling of cancer patients enables personalized combination therapy: the I‐PREDICT study publication-title: Nat Med – volume: 27 start-page: 1386 year: 2016 end-page: 1422 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann Oncol – volume: 37 year: 2019 article-title: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors publication-title: J Clin Oncol – volume: 16 start-page: 1324 year: 2015 end-page: 1334 article-title: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open‐label, proof‐of‐concept, randomised, controlled phase 2 trial publication-title: Lancet Oncol – volume: 21 start-page: 796 year: 2020 end-page: 807 article-title: Ivosidenib in IDH1‐mutant, chemotherapy‐refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double‐blind, placebo‐controlled, phase 3 study publication-title: Lancet Oncol – volume: 30 start-page: 757 year: 2019 end-page: 765 article-title: Molecular screening program to select molecular‐based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial publication-title: Ann Oncol – volume: 110 start-page: 1464 year: 2019 end-page: 1479 article-title: Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin‐fixed paraffin‐embedded specimens publication-title: Cancer Sci – volume: 360 start-page: 1408 year: 2009 end-page: 1417 article-title: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer publication-title: N Engl J Med – volume: 21 start-page: 508 year: 2020 end-page: 518 article-title: Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial publication-title: Lancet Oncol – volume: 110 start-page: 1480 year: 2019 end-page: 1490 article-title: Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: a hospital‐based study publication-title: Cancer Sci – volume: 23 start-page: 703 year: 2017 end-page: 713 article-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients publication-title: Nat Med – volume: 108 start-page: 1440 year: 2017 end-page: 1446 article-title: Clinical sequencing using a next‐generation sequencing‐based multiplex gene assay in patients with advanced solid tumors publication-title: Cancer Sci – volume: 1 start-page: PO.17.00011. year: 2017 article-title: OncoKB: A precision oncology knowledge base publication-title: JCO Precis Oncol – volume: 19 start-page: 249 year: 2017 end-page: 255 article-title: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics publication-title: Genet Med – volume: 35 start-page: 1453 year: 2017 end-page: 1486 article-title: Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology publication-title: J Clin Oncol – year: 2020 – volume: 31 start-page: 1023 year: 2013 end-page: 1031 article-title: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing publication-title: Nat Biotechnol – volume: 1 start-page: 1 year: 2017 end-page: 19 article-title: Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins molecular tumor board publication-title: JCO Precis Oncol – volume: 38 year: 2020 article-title: Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM‐Japan GI‐SCREEN and GOZILA Combined Analysis publication-title: J Clin Oncol – volume: 109 start-page: 2980 year: 2018 end-page: 2985 article-title: Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0) publication-title: Cancer Sci – ident: e_1_2_9_17_1 doi: 10.1200/JOP.2014.002303 – ident: e_1_2_9_14_1 doi: 10.1038/s41591-019-0407-5 – ident: e_1_2_9_16_1 doi: 10.1016/S1470-2045(20)30074-7 – volume: 1 start-page: PO.17.00011. year: 2017 ident: e_1_2_9_13_1 article-title: OncoKB: A precision oncology knowledge base publication-title: JCO Precis Oncol – ident: e_1_2_9_2_1 doi: 10.1056/NEJMra1615014 – ident: e_1_2_9_3_1 doi: 10.1038/nm.4333 – ident: e_1_2_9_5_1 doi: 10.1111/cas.13265 – ident: e_1_2_9_8_1 doi: 10.1093/annonc/mdz080 – ident: e_1_2_9_21_1 doi: 10.1111/cas.14290 – ident: e_1_2_9_19_1 doi: 10.1093/annonc/mdw235 – ident: e_1_2_9_26_1 doi: 10.1038/gim.2016.190 – ident: e_1_2_9_12_1 doi: 10.1111/cas.13730 – ident: e_1_2_9_18_1 doi: 10.1200/JCO.2016.71.9807 – ident: e_1_2_9_6_1 doi: 10.1111/cas.13969 – ident: e_1_2_9_4_1 doi: 10.1093/jjco/hyw018 – ident: e_1_2_9_7_1 doi: 10.1016/S1470-2045(15)00188-6 – ident: e_1_2_9_10_1 doi: 10.1056/NEJMoa0805019 – ident: e_1_2_9_23_1 doi: 10.1200/JCO.2019.37.15_suppl.3003 – volume: 29 ident: e_1_2_9_25_1 article-title: Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations publication-title: Ann Oncol – ident: e_1_2_9_24_1 doi: 10.1016/S1470-2045(20)30157-1 – volume: 1 start-page: 1 year: 2017 ident: e_1_2_9_15_1 article-title: Personalized medicine in the oncology clinic: implementation and outcomes of the Johns Hopkins molecular tumor board publication-title: JCO Precis Oncol doi: 10.1200/PO.16.00046 – ident: e_1_2_9_9_1 doi: 10.1038/nbt.2696 – ident: e_1_2_9_11_1 – ident: e_1_2_9_20_1 doi: 10.1111/cas.13968 – volume: 38 year: 2020 ident: e_1_2_9_22_1 article-title: Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM‐Japan GI‐SCREEN and GOZILA Combined Analysis publication-title: J Clin Oncol |
| SSID | ssj0036494 |
| Score | 2.4742517 |
| Snippet | Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to... Comprehensive genomic profiling (CGP) testing by next-generation sequencing has been introduced into clinical practice as part of precision cancer medicine to... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 296 |
| SubjectTerms | actionable genomic alteration Adult Aged Aged, 80 and over Biomarkers Biomarkers, Tumor - genetics Cancer Cancer therapies Chemotherapy Clinical medicine Clinical Research Clinical trials Colorectal cancer Colorectal carcinoma comprehensive genomic profiling druggable genomic alteration Esophageal cancer FDA approval Feasibility studies Female Gastric cancer gastrointestinal cancer Gene Expression Profiling - methods Genetic counseling Growth factors Health insurance High-Throughput Nucleotide Sequencing - methods Humans Kinases Male Medical research Medicine Middle Aged Molecular Targeted Therapy - methods Mutation Neoplasms - genetics Original Pancreatic cancer Patients precision cancer medicine Precision Medicine - methods Prospective Studies Sequence Analysis, DNA - methods Tumors Young Adult |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3BTtwwEB1RkBCXilJaFihyUQ-9WM3GTpwcKkQRCFVihdqicosmjiOQIEt3lwO3fkL_hI_gT_olzDjOlhXQ00byRFl77PGzPX4P4INFlyJWTqYZJlKbMpWYJLWkqS4qy4r5Qfhy8tEgPTzRX0-T0zkYdHdhOK2yi4k-UFdDy3vkn2JNwJeWcpHZufolWTWKT1c7CQ0M0grVZ08x9gIWKCRn1O8XvuwPjr91sVmlOm9lbrWReaTiwDXEuT0sMcZhQ8_OUI9g5-PsyYeo1k9LB8vwMuBJsdt2gFcw55oVWDwKJ-av4ScP-JE7a_PUBVOyXp5b0Up107QlCLSKQK46FrwrK8iNl-Fe1s3f338avLulN7tkAWH5Z7QKJwf7P_YOZRBTkDZJlJZUxUgRdrO1KpnCp9RW9esc67pyWBvrCGmkmbEGIxdhvzZVptFiYpiUK85RvYH5Zti4NRBaUUzUpsotoqbynJUJTYwKy8wRYuvBx64BCxuYxlnw4qLoVhzU1oVv6x5sT02vWnqNp4w2Oy8UYYSNi3_9oQfvp8U0NvjAAxs3vGYbnTEg7ZPN29Zp068o5RfoWQ_MjDunBsy7PVvSnJ95_m1jCGWrmKrpHf_8Hy_2dr_7h_X_12ADlmJOlfE7O5swPxldu3eEdSblVujA9zHjASs priority: 102 providerName: ProQuest |
| Title | Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14674 https://www.ncbi.nlm.nih.gov/pubmed/33007138 https://www.proquest.com/docview/2474769007 https://www.proquest.com/docview/2448405717 https://pubmed.ncbi.nlm.nih.gov/PMC7780032 |
| Volume | 112 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NSuRAEC5mFWQvsv6Pq0MrHrwEMulOOmFPKjMMgiL-4NxCpdNBQaPM6MGbj7Bvsg-xb7JPslWdHxxU8JIEupqku1LdX3VXfwWwZ9BGiLn1ohhDT-ks8jAMC4-mOj_LcuYH4cPJJ6fR6Eodj8NxB341Z2Eqfoh2wY0tw43XbOCYTd8YOacEYzNX32Cej9Zy3oZAnTXDsIxUUmW0VdpLfBnUtEIcxtNWnZ2M3iHM94GSbwGsm4GGP2Cxho7ioNL1EnRsuQwLJ_Xm-Apcs21P7E0Vki6YffX-1ogqKzfNUILwqah5VKeCF2AFaey-PoL18u_1d4l__1DNJi5AGL5NVuFqOLg8Gnl13gTPhKFUHjXRlwTTTCEzZuvJlJH9IsGiyC0W2lgCFVGsjUbf-tgvdB4rNBhq5t8KEpRrMFc-lHYDhJI0_CmdJwZRUXnCSQh1gBKz2BI468J-04GpqUnFObfFXdo4F9TXqevrLuy2oo8Vk8ZHQluNFtLamKZpoMjnIS_e113YaYvJDHhvA0v78MwyKmbs2SeZ9Upp7VukdL543AU9o85WgCm2Z0vK2xtHta01AWoZUDOd4j__8PTo4MI9bH5d9Cd8DzhCxi3obMHc0-TZbhPEecp67lemqx7rHswfDk7PzntuuYCv58F_xRL-3Q |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VrQS9IH7bhQIGgcTFIhs7cXKoqlJabWl3haAVvYWJ46iV2mzZbYV64xF4k74BF96EJ2EmcRZWBW49ZSXPbtYee-azPfMNwHOLLkYsnIwTjKQ2eSwxikpJri7I84L5QTg5eTCM-3v67X60Pwff21wYDqtsbWJtqIuR5TPyV6Em4EtbucCsnnyWXDWKb1fbEhroSysUKzXFmE_s2HbnX2gLN1nZekP6fhGGmxu7633pqwxIG0VKS1rsgSJQY0uVM7dNrq3qlSmWZeGwNNaRC44TYw0GLsBeaYpEo8XIMFtVmKKi370G85ozXDsw_3pj-O596wtUrNOmrK42Mg1U6LmNOJaIS5qxmdKzHvESzL0crfkniq7d4OYtuOnxq1hrJtxtmHPVHbg-8Df0d-EjG5ixO2ji4gVTwB4fWtGUBic3KQgkC0_mOhF8Cixo2hz7PLDzn1-_Vfjjgr7ZBicIy4_xPdi7kmG9D51qVLklEFqRDdamSC2ipvaUKyGaEBXmiSOE2IWX7QBm1jObc4GNo6zd4dBYZ_VYd-HZVPSkofP4m9Byq4XMr-hJ9nv-deHptJnWIl-wYOVGZyyjEwbAPZJZbJQ2fYtS9YFA0gUzo86pAPN8z7ZUhwc137cxhOpVSN2sFf_vP56tr32oPzz4fw-ewI3-7mAn29kabj-EhZDDdOpTpWXonI7P3CPCWaf5Yz-ZBXy66vXzC6ehPZI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NTtwwEB7RRUK9VPR_C23dqpV6icjGTpwcUEWBFZSyQm1RuYWJ4wikkoVdEOLGI_AmfYje-hh9ks44zrYr2t44ZSXPbtYez8xne_wNwCuDNkEsbZCkGAdKF0mAcVwFFOrCoiiZH4QvJ28Pko1d9X4v3puBH-1dGE6rbH2ic9Tl0PAe-VKkCPjSUi7US5VPi9hZ6789Pgm4ghSftLblNNCXWSiXHd2Yv-SxZS_OaTk3Xt5cI92_jqL--ufVjcBXHAhMHEsVkOGHkgCOqWTBPDeFMrJXZVhVpcVKG0vhOEm10RjaEHuVLlOFBmPNzFVRhpJ-9xbMaoqSqgOz79YHOx_buCATlTUldpUOslBGnueI84q4vBm7LDUdHa9B3uuZm38iahcS-_Nwx2NZsdJMvrswY-t7MLftT-vvwxd2NiN70OTIC6aDPTo0oikTTiFTEGAWnth1LHhHWNAUOvJ3wi5-Xl7V-P0bfbNNVBCGH6MHsHsjw_oQOvWwto9BKEn-WOkyM4iK2jOuiqgjlFikltBiF960A5gbz3LOxTa-5u1qh8Y6d2PdhZcT0eOG2uNvQoutFnJv3eP891zswotJM9klH7ZgbYdnLKNSBsM9knnUKG3yFind5kDaBT2lzokAc35Pt9SHB477W2tC-DKibjrF__uP56srn9yHJ__vwXOYIzvKP2wOthbgdsQZO26DaRE6p6Mz-5Qg12nxzM9lAfs3bT6_ACQWQb4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+genomic+profiling+for+patients+with+chemotherapy%E2%80%90na%C3%AFve+advanced+cancer&rft.jtitle=Cancer+science&rft.au=Kondo%2C+Tomohiro&rft.au=Matsubara%2C+Junichi&rft.au=Quy%2C+Pham+Nguyen&rft.au=Fukuyama%2C+Keita&rft.date=2021-01-01&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=112&rft.issue=1&rft.spage=296&rft.epage=304&rft_id=info:doi/10.1111%2Fcas.14674&rft.externalDBID=10.1111%252Fcas.14674&rft.externalDocID=CAS14674 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |